← All trials
NCT06608641
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 19, 2024
- Primary completion
- Jun 30, 2025
- Completion date
- Sep 30, 2025
- First posted
- Sep 23, 2024
- Last posted
- Sep 23, 2024
- Enrollment
- 490
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jina Pharmaceuticals, Inc.Lead sponsor
- Novum Pharmaceutical Research ServicesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.